Pankti Reid to Neoplasms
This is a "connection" page, showing publications Pankti Reid has written about Neoplasms.
Connection Strength
1.731
-
Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. J Cancer Educ. 2023 10; 38(5):1486-1492.
Score: 0.298
-
Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022 12; 36(4):101805.
Score: 0.292
-
Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol. 2022 Oct 01; 28(7):367-373.
Score: 0.281
-
Immune Checkpoint Inhibitor Therapy Toxicities-Reply. JAMA. 2021 07 06; 326(1):87-88.
Score: 0.264
-
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 02; 325(5):482-483.
Score: 0.256
-
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 Nov 04; 7(11):e2446336.
Score: 0.083
-
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22(9):582-592.
Score: 0.083
-
Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care. Rheum Dis Clin North Am. 2024 05; 50(2):229-239.
Score: 0.079
-
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
Score: 0.076
-
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis. Rheum Dis Clin North Am. 2024 05; 50(2):161-179.
Score: 0.020